Prognostic and predictive value of YKL-40 in stage IIB-III melanoma
| العنوان: | Prognostic and predictive value of YKL-40 in stage IIB-III melanoma |
|---|---|
| المؤلفون: | Ib Jarle Christensen, Julia S. Johansen, Lars Bastholt, Stefan Suciu, Henrik Schmidt, Merete Krogh, Marna G. Bouwhuis, Johan Hansson, Alexander M.M. Eggermont, Peter Nørgaard |
| المساهمون: | Emergency Medicine, Epidemiology |
| المصدر: | Krogh, M, Christensen, I, Bouwhuis, M, Johansen, J S, Nørgaard, P, Schmidt, H, Hansson, J, Suciu, S, Eggermont, A M M, Bastholt, L & Nordic Melanoma Group and EORTC Melanoma Group 2016, ' Prognostic and predictive value of YKL-40 in stage IIB-III melanoma ', Melanoma Research, vol. 26, no. 4, pp. 367-76 . https://doi.org/10.1097/CMR.0000000000000237Test Krogh, M, Christensen, I, Bouwhuis, M, Johansen, J S, Nørgaard, P, Schmidt, H, Hansson, J, Suciu, S, Eggermont, A M M, Bastholt, L & Nordic Melanoma Group and EORTC Melanoma Group 2016, ' Prognostic and predictive value of YKL-40 in stage IIB-III melanoma ', Melanoma Research, vol. 26, no. 4, pp. 367-376 . https://doi.org/10.1097/CMR.0000000000000237Test Melanoma Research, 26(4), 367-376. Lippincott Williams & Wilkins |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Oncology, musculoskeletal diseases, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, Alpha interferon, Dermatology, Interferon alpha-2, CHI3L1, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Biomarkers, Tumor, medicine, Journal Article, Humans, Chitinase-3-Like Protein 1, Prospective Studies, Prospective cohort study, Melanoma, Lymph node, Aged, Neoplasm Staging, Univariate analysis, business.industry, Hazard ratio, Interferon-alpha, Cancer, Middle Aged, Prognosis, medicine.disease, Recombinant Proteins, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, business |
| الوصف: | This study investigates the prognostic and predictive value of YKL-40 in stage IIB-III melanoma patients who were randomized to adjuvant interferon α-2b (IFN) or observation. Serum YKL-40 was determined postoperatively in patients from the Nordic IFN Trial (n=602), EORTC 18952 (n=246), and EORTC 18991 (n=386) (EORTC, European Organisation for Research and Treatment of Cancer). YKL-40 protein expression was determined in 300 tissue sections of primary melanoma or lymph node metastases from 204 Danish patients from the Nordic IFN Trial. Multivariate Cox analysis (including sex, age, stage, ulceration, YKL-40) showed that elevated baseline YKL-40 level was associated with shorter overall survival (OS) in observation groups from the Nordic IFN Trial and EORTC 18952 [hazard ratio (HR)=1.33; 95% confidence interval (CI) 1.01-1.74; P=0.04], but not in the interferon groups (1-year IFN: HR=0.97; 95% CI 0.76-1.25; P=0.83; 2-years IFN: HR=1.06; 95% CI 0.83-1.34; P=0.64). During follow-up, increases in YKL-40 were significantly associated with shorter OS, but not with recurrence-free survival in univariate analysis. YKL-40 expression was stronger in tumor-associated macrophages than melanoma cells in primary melanoma. High YKL-40 expression in macrophages in lymph node metastases was associated with shorter OS in the observation group (HR=2.76; 95% CI: 1.13-6.76, P=0.02), but not in the interferon-treated groups. YKL-40 was an independent prognostic biomarker of OS in melanoma patients stage IIB-III. High serum YKL-40 in poor-prognosis patients may originate from macrophages in the tumor microenvironment and the melanoma cells. Furthermore, we hypothesize that elevated serum YKL-40 after surgery may predict the efficacy of adjuvant IFN treatment. This study investigates the prognostic and predictive value of YKL-40 in stage IIB-III melanoma patients who were randomized to adjuvant interferon α-2b (IFN) or observation. Serum YKL-40 was determined postoperatively in patients from the Nordic IFN Trial (n=602), EORTC 18952 (n=246), and EORTC 18991 (n=386) (EORTC, European Organisation for Research and Treatment of Cancer). YKL-40 protein expression was determined in 300 tissue sections of primary melanoma or lymph node metastases from 204 Danish patients from the Nordic IFN Trial. Multivariate Cox analysis (including sex, age, stage, ulceration, YKL-40) showed that elevated baseline YKL-40 level was associated with shorter overall survival (OS) in observation groups from the Nordic IFN Trial and EORTC 18952 [hazard ratio (HR)=1.33; 95% confidence interval (CI) 1.01-1.74; P=0.04], but not in the interferon groups (1-year IFN: HR=0.97; 95% CI 0.76-1.25; P=0.83; 2-years IFN: HR=1.06; 95% CI 0.83-1.34; P=0.64). During follow-up, increases in YKL-40 were significantly associated with shorter OS, but not with recurrence-free survival in univariate analysis. YKL-40 expression was stronger in tumor-associated macrophages than melanoma cells in primary melanoma. High YKL-40 expression in macrophages in lymph node metastases was associated with shorter OS in the observation group (HR=2.76; 95% CI: 1.13-6.76, P=0.02), but not in the interferon-treated groups. YKL-40 was an independent prognostic biomarker of OS in melanoma patients stage IIB-III. High serum YKL-40 in poor-prognosis patients may originate from macrophages in the tumor microenvironment and the melanoma cells. Furthermore, we hypothesize that elevated serum YKL-40 after surgery may predict the efficacy of adjuvant IFN treatment. |
| تدمد: | 0960-8931 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27c2b4a125a416d8f3a3851aa358d182Test https://doi.org/10.1097/cmr.0000000000000237Test |
| حقوق: | RESTRICTED |
| رقم الانضمام: | edsair.doi.dedup.....27c2b4a125a416d8f3a3851aa358d182 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 09608931 |
|---|